At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMLX Amylyx Pharmaceuticals
Closed 08-21 16:00:00 EDT
38.66
-1.00
-2.52%
盘后39.00
+0.34+0.88%
19:55 EDT
High41.14Low38.35Vol4.64M
Open39.80D1 Closing39.66Amplitude7.03%
Mkt Cap4.30BTradable Cap3.19BTotal Shares111.19M
T/O182.75MT/O Rate5.63%Tradable Shares82.57M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

ETF Weekly | ETHU Jumps 62%; NUGT Climbs 29%; SMST, MSTZ Sink 45%; Crypto Leverage Sets the Pace
ETF Weekly  ·  08:01
ETF Weekly | ETHU Jumps 62%; NUGT Climbs 29%; SMST, MSTZ Sink 45%; Crypto Leverage Sets the Pace
Amylyx Pharmaceuticals Announces Equity Offering to Fund Avexitide
TIPRANKS  ·  08-21 05:59
Amylyx Pharmaceuticals Announces Equity Offering to Fund Avexitide
Chevron Stock (CVX) Breaks Past $196 Resistance as Strong Crude Prices Fuel Growth
TIPRANKS  ·  08-21 00:14
Chevron Stock (CVX) Breaks Past $196 Resistance as Strong Crude Prices Fuel Growth
U.S. Stocks on the MOVE-Apple, Hims & Hers Health, Sysco
Reuters  ·  08-20 23:39
U.S. Stocks on the MOVE-Apple, Hims & Hers Health, Sysco
Amylyx Dips After Increased $500 Mln Stock Sale to Fund Blood Sugar Drug
Reuters  ·  08-20 19:33
Amylyx Dips After Increased $500 Mln Stock Sale to Fund Blood Sugar Drug
Amylyx Prices Upsized 14,090,000-Share Follow-on at $35.5/share for $500.2 Million Gross Proceeds
Reuters  ·  08-20 11:06
Amylyx Prices Upsized 14,090,000-Share Follow-on at $35.5/share for $500.2 Million Gross Proceeds
Amylyx Pharmaceuticals, - Announces Upsized Public Offering of 14,090,000 Shares at $35.50 Per Share
THOMSON REUTERS  ·  08-20 11:06
Amylyx Pharmaceuticals, - Announces Upsized Public Offering of 14,090,000 Shares at $35.50 Per Share
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
THOMSON REUTERS  ·  08-20 11:06
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
APA Group Releases Updated Corporate Governance Statement
TIPRANKS  ·  08-20 07:23
APA Group Releases Updated Corporate Governance Statement
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA) and Merck & Company (MRK)
TIPRANKS  ·  08-19 21:50
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA) and Merck & Company (MRK)
U.S. Research Roundup-Cogent Communications, Dollar Tree, Home Depot
Reuters  ·  08-19 15:50
U.S. Research Roundup-Cogent Communications, Dollar Tree, Home Depot
Amylyx Pharmaceuticals, Inc. : Baird Raises Target Price to $52 from $28
THOMSON REUTERS  ·  08-19 10:49
Amylyx Pharmaceuticals, Inc. : Baird Raises Target Price to $52 from $28
Amylyx Launches USD 350 Million Follow-on Common Stock Offering
Reuters  ·  08-19
Amylyx Launches USD 350 Million Follow-on Common Stock Offering
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock
THOMSON REUTERS  ·  08-19
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock
Amylyx Pharmaceuticals, - Proceeds to Fund Avexitide Pre-Commercial Activities, R&D, and General Corporate Purposes
THOMSON REUTERS  ·  08-19
Amylyx Pharmaceuticals, - Proceeds to Fund Avexitide Pre-Commercial Activities, R&D, and General Corporate Purposes
Amylyx Pharmaceuticals Price Target Raised to $55.00/Share from $34.00 by HC Wainwright & Co.
Dow Jones  ·  08-19
Amylyx Pharmaceuticals Price Target Raised to $55.00/Share from $34.00 by HC Wainwright & Co.
U.S. Stocks on the MOVE-Gold Miners, Weave Communications, Amylyx Pharmaceuticals
Reuters  ·  08-19
U.S. Stocks on the MOVE-Gold Miners, Weave Communications, Amylyx Pharmaceuticals
Wall Street Analysts Are Bullish on Top Healthcare Picks
TIPRANKS  ·  08-19
Wall Street Analysts Are Bullish on Top Healthcare Picks
Amylyx price target raised to $55 from $34 at H.C. Wainwright
TIPRANKS  ·  08-19
Amylyx price target raised to $55 from $34 at H.C. Wainwright
Amylyx Pharmaceuticals up over 50%, on Pace for Largest Percent Increase Since September 2022
Dow Jones  ·  08-18
Amylyx Pharmaceuticals up over 50%, on Pace for Largest Percent Increase Since September 2022

Introduction

Company Name.
Amylyx Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Issue price:
--